Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Grand Pharmaceutical Group Limited ( (HK:0512) ) has shared an update.
Grand Pharmaceutical Group Limited announced that its SIR-Spheres® Y-90 resin microsphere injection has received CE Mark approval in Europe for new indications in the treatment of liver cancer, expanding its application to include various types of unresectable liver tumors. This development, alongside recent FDA approval in the United States, enhances the company’s market positioning and demonstrates its strong clinical registration and commercial capabilities, supporting its global expansion strategy in nuclear medicine.
The most recent analyst rating on (HK:0512) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a company involved in the pharmaceutical industry, focusing on innovative nuclear medicine products. The company operates globally, with a strategic emphasis on the development, production, and sales of anti-tumor diagnostic and treatment products, particularly in the field of nuclear medicine.
Average Trading Volume: 24,416,929
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.88B
Find detailed analytics on 0512 stock on TipRanks’ Stock Analysis page.